Chemesis International Inc. Announces Addition of Chief Science Officer, Dr. Joshua Hartsel
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. Announces Addition of Chief Science Officer, Dr. Joshua Hartsel
Dr. Hartsel has extensive experience in large scale commercial extraction facilities
July 15, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), announces the addition of Chief Science Officer, Dr. Joshua Hartsel, a leader in the Research
and Development of cannabis and hemp extraction technologies across the industry.
Dr. Hartsel’s experience in the cannabis industry has a special focus on extraction and finished goods
manufacturing. His experience working with both THC & CBD on a commercial scale and building several
startups offers significant value to the team. Chemesis is primarily focused on ensuring product
consistency and quality, with his guidance, the company will exceed those objectives.
Dr. Hartsel earned his Ph.D. from Virginia Polytechnic Institute and State University in Medicinal Organic
Chemistry, and received his Bachelor’s of Science in Chemistry from Radford University. Continuing his
graduate studies on malaria insecticides with the Bill and Melinda Gates Foundation, Dr. Hartsel also spent
several years at the University of California, Irvine as a postdoctoral fellow in the Public Health
Department.
Dr. Hartsel previous working experience in the cannabis industry includes:
• Chief Executive Officer of Delta-9 Technologies , where he leads the company’s successful
development of industrial-scale automated hydrocarbon extractors.
• Chief Executive Officer of Blue Sky Technologies, where he develops industrial scale extraction of
cannabidiol (CBD) and rare non-psychoactive cannabinoid and supplements.
• Chief Science Officer at Ananda Hemp, where Dr. Hartsel designed and managed the build of a
commercial scale extraction laboratory.
• In addition, Dr. Hartsel has worked as the Director of R&D for Privateer Holdings and CV Sciences,
where he assisted in the development and strategic investments into cannabis products.
“Chemesis has assembled an asset portfolio that I believe my expertise can be leveraged,” said Dr. Joshua
Hartsel. “I look forward to working together with t he Chemesis’ team and the extraction facilities to
further add efficiencies and increase the Company’s capabilities.”
“The addition of Dr. Hartsel brings a wealth of hands on experience in commercial scale extraction but
also relationships that will allow the Company to continue to grow our extraction services ,” said CEO of
Chemesis, Edgar Montero. “His education and experience will allow Chemesis to continue to delivery high
quality products and excel in its manufacturing capabilities.”
On Behalf of The Board of Directors
Edgar Montero
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi -State operator with International
operations in Puerto Rico, and Colombia.
The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it
enters new markets and is committed to differentiate itself by deploying resources in markets with major
opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis
consumers, with focus on quality and consistency.
Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP
certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft 2 of
cultivation, and 35,000 ft 2 of manufacturing flo or space. The Company is positioned to win additional
licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a
first mover advantage.
Investor Relations:
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "forward -looking information" within the meaning of
applicable securities laws relating to statements regarding the Company's business, products and future of the
Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in
Colombia. Although the Company believes that the expectations re flected in the forward -looking information are
reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to
place undue reliance on forward -looking information. Such forward -looking statements are subj ect to risks and
uncertainties that may cause actual results, performance and developments to differ materially from those
contemplated by these statements depending on, among other things, the risks that the Company's products and
plan will vary from those stated in this news release and the Company may not be able to carry out its business plans
as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update
any forward-looking statements or forward-looking information in this news release. Although the Company believes
that the expectations reflected in the forward -looking information are reasonable, there can be no assurance that
such expectations will prove to be correct and makes no reference to prof itability based on sales reported. The
statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.